1. Home
  2. MRUS

MRUS

Merus N.V.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 11:31am EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Founded: 2003 Country:
Netherlands
Netherlands
Employees: N/A City: 3584 CM UTRECHT
Market Cap: 2.3B IPO Year: 2016
Target Price: $54.50 AVG Volume (30 days): 559.7K
Analyst Decision: Strong Buy Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.00 EPS Growth: N/A
52 Week Low/High: $18.21 - $52.04 Next Earning Date: 05-02-2024
Revenue: $43,947,000 Revenue Growth: 5.68%
Revenue Growth (this year): -3.93% Revenue Growth (next year): 57.12%

Share on Social Networks:

Stock Insider Trading Activity of Merus N.V. (MRUS)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Shuman Harry MRUS VP Controller, PAO Dec 19 '23 Sell $26.68 115 $3,068.20 7,002 SEC Form 4
Shuman Harry MRUS VP Controller, PAO Dec 8 '23 Sell $24.44 250 $6,110.00 7,117 SEC Form 4
Shuman Harry MRUS VP Controller, PAO Dec 1 '23 Sell $24.58 575 $14,133.50 7,367 SEC Form 4